Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Potency and Efficacy of Pharmacological PIP4K2 Inhibitors in Acute Lymphoblastic Leukemia

Keli Lima, Maria Fernanda Lopes Carvalho, Diego A. Pereira-Martins, Wellington F Silva, Mariane Cristina do Nascimento, Lívia Bassani Lins de Miranda, Rita de Cássia Cavaglieri Medeiros, Luciana Nardinelli, Aline de Medeiros Leal, Elvira Deolinda Rodrigues Pereira Velloso, Israel Bendit, Jan Jacob Schuringa, João Agostinho Machado-Neto, Eduardo Magalhães Rego

Blood (2023) 142 (Supplement 1): 5786.

https://doi.org/10.1182/blood-2023-189786

Published: 2023

Journal Articles

Real-World Data for FLT3-Mutated Acute Myeloid Leukemia Patients Treated in Resource-Constrained Settings

Wellington F Silva, Fernanda Rodrigues Mendes, Marco Sartori, Maria Isabel A Madeira, Katia B Pagnano, Ana Beatriz F Gloria, Elenaide C. Nunes, Luciana Nardinelli, Rita De Cássia Cavaglieri Medeiros, Israel Bendit, Fabiola Traina, Bruno Kosa Lino Duarte, Lorena Lobo Figueiredo-Pontes, Vanderson Rocha, Elvira Deolinda Rodrigues Pereira Velloso, Eduardo Magalhães Rego

Blood (2023) 142 (Supplement 1): 5839.

https://doi.org/10.1182/blood-2023-187902

Published: 2023

Journal Articles

Treatment- Free Remission in Chronic Myeloid Leukemia -Experience of a Single Brazilian Private Institution Using Imatinib Copies

Renato Torrescasana Centrone, Marcelo Bellesso, Rodrigo Santucci Silva, Daniela Ferreira Dias, Israel Bendit, Jhony ARANHA Lima Alves, Felipe Ribeiro Bruniera, Ariel Testasicca Trunkel, Adelson Alves da Silva, Sr.

Blood (2022) 140 (Supplement 1): 12226–12227.

https://doi.org/10.1182/blood-2022-157425

Published: 2022

Journal Articles

Treatment-Free Response in Chronic Myeloid Leukemia Using Brazilian Imatinib Copies As First Line - Results from Two Prospective Clinical Trials

Renato Torrescasana Centrone, Fernanda S Seguro, Marcelo Bellesso, Luciana Nardinelli, Israel Bendit, Vanderson Rocha, Adelson Alves

Blood (2022) 140 (Supplement 1): 12200–12201.

https://doi.org/10.1182/blood-2022-158969

Published: 2022

Journal Articles

Rhoa Mutation Is a Potential Biomarker Associated with Adverse Prognosis and High- Tumor Burden in Patients with Nodal Peripheral Lymphomas with T-Helper Follicular Phenotype (nPTCL-Thf): Data from a Brazilian Retrospective Cohort of Nodal PTCL

Luis Alberto de Padua Covas Lage, Guilherme Carneiro Barreto, Hebert Fabricio Culler, Jéssica Billar Cavalcanti, Lucas de Oliveira Alves, Luciana Nardinelli, Israel Bendit, Vanderson Rocha, Juliana Pereira

Blood (2021) 138 (Supplement 1): 4482.

https://doi.org/10.1182/blood-2021-148503

Published: 2021

Journal Articles

Chronic Myeloid Leukemia: Comparison of Survival between Pregnant and Non-Pregnant Women

Giovanna Iantevi Ghelfond, MD, Fernanda Santos, MD, Fernanda S Seguro, MD, Andre Abdo, MD, Thales Pereira, MD, Felipe VR Maciel, MD, Lucas BO Alves, PhD, Israel Bendit, MD PhD, Vanderson Rocha, MD PhD, Eduardo M Rego, MDPhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-142098

Published: 2020

Journal Articles

Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country

Antonio Adolfo Guerra Soares Brandão, MD, Giancarlo Fatobene, MD, Andre Abdo, MD, Luis Alberto de Padua Covas Lage, MD PhD, Israel Bendit, MD PhD, Luciana Nardinelli, MSc, Sheila Aparecida Coelho de Siqueira, MD PhD, Debora Levy, MSc, PhD, Juliana Pereira, MD PhD, Eduardo M Rego, MDPhD, Vanderson Rocha, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-142617

Published: 2020

Journal Articles

COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-138563

Published: 2020

Journal Articles

Co-occurrence of DNMT3A , NPM1 , FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis

Blood (2020) 135 (11): 870–875.

https://doi.org/10.1182/blood.2019003339

Published: 2020

Includes: Supplemental data

Journal Articles

Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial

Fernanda S Seguro, MD, Felipe VR Maciel, MD, Guilherme O Lopes, Luciana Nardinelli, M.Sc, Vanderson Rocha, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1651.

https://doi.org/10.1182/blood-2019-125989

Published: 2019

Journal Articles

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Katia B Pagnano, MD PhD, Fernanda S Seguro, MD, Eliana C Miranda, PhD, Ana Beatriz Pascoal Lopes, Andre Abdo, MD, Marcia Torresan Delamain, MD, Thales Pereira, MD, Gislaine Borba Duarte, MD, Fernanda Maria Santos, Jessica CN Vianna, Matheus Sebastian Da Silva, Luciana Nardinelli, M.Sc, Valquiria Povoa, Graziele Pavan, Bruna R Vergilio, Vanderson Rocha, MD PhD, Carmino Antonio Souza, MD PhD, Erich V De Paula, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1655.

https://doi.org/10.1182/blood-2019-125368

Published: 2019

Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Blood (2019) 134 (Supplement_1): 2924.

https://doi.org/10.1182/blood-2019-128761

Published: 2019

Journal Articles

Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts

Douglas R. A. Silveira, Lynn Quek, MD PhD, Anna Corby, B.Sc., Juan L Coelho-Silva, BSc, MSc, Diego A Pereira-Martins, MSc, Grant Vallance, B.Sc., PhD, Benjamin Brown, B.Sc., PhD, Luciana Nardinelli, M.Sc, Wellington F Silva, MD, Elvira DRP Velloso, MD PhD, Fabiola Traina, MD PhD, Andy Peniket, MD, Paresh Vyas, MD PhD, Eduardo M Rego, MD PhD, Israel Bendit, MD PhD, Vanderson Rocha, MD PhD

Blood (2019) 134 (Supplement_1): 2602.

https://doi.org/10.1182/blood-2019-130726

Published: 2019

Journal Articles

Molecular-Based Score Inspired on Metabolic Signature Improves Prognostic Stratification for Myelodysplastic Syndrome

Juan L Coelho-Silva, BSc, MSc, Douglas R. A. Silveira, Diego A Pereira-Martins, MSc, César Alexander Ortiz Rojas, BSc, Antonio R. Lucena-Araujo, PhD, Eduardo M Rego, MD PhD, João Agostinho Machado-Neto, PhD, Israel Bendit, MD PhD, Vanderson Rocha, MD PhD, Fabiola Traina, MD PhD

Blood (2019) 134 (Supplement_1): 4257.

https://doi.org/10.1182/blood-2019-132141

Published: 2019

Journal Articles

Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study

Renato Torrescasana Centrone, Isabel Bonafe, Eliana C Miranda, PhD, Fernanda S Seguro, MD, Gustavo HR Magalhaes, MD MSc, Nelma D Clementino, MD, Arthur Moellmann-Coelho, MD, Ingrid Luise, MD, Monika Conchon, MD, Natália N Gonçalves, MD, Jaisson Bortolini, MD, Laura Maria Fogliatto, MD PhD, Carmino Antonio Souza, MD PhD, Katia B Pagnano, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 5844.

https://doi.org/10.1182/blood-2019-127530

Published: 2019

Journal Articles

Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia

Blood (2019) 134 (12): 951–959.

https://doi.org/10.1182/blood.2019000239

Published: 2019

Journal Articles

WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil

Elvira DRP Velloso, MD PhD, Maria Gabriella Cordeiro, Danielle Lucon, PhD, Renata Kishimoto, Aline Medeiros Leal, PhD, Ana Carolina Arrais Maia, MD, Valeria Buccheri, MD PhD, Israel Bendit, MD PhD, Wellington Fernandes Silva, Jr., MD, Cristovao Mangueira, MD PhD, Eduardo Magalhães Rego, MD PhD, Vanderson Rocha, MD PhD

Blood (2018) 132 (Supplement 1): 5288.

https://doi.org/10.1182/blood-2018-99-115426

Published: 2018

Journal Articles

Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study

Blood (2018) 132 (Supplement 1): 46.

https://doi.org/10.1182/blood-2018-99-113718

Published: 2018

Journal Articles

Impact of Treatment Free Remission (TFR) with Nilotinib in 2 nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment

Andre Abdo, MD, Carla Maria Boquimpani, MD, Douglas Vivona, PhD, Viviane Silveira Leite, BSC, Alisson L. Matsuo, PhD, Vanessa Teich, BSC, Israel Bendit, MD PhD, Eduardo Magalhães Rego, MD PhD, Vanderson Rocha, MD PhD

Blood (2018) 132 (Supplement 1): 4760.

https://doi.org/10.1182/blood-2018-99-119200

Published: 2018

Journal Articles

E14a2 and e14a2+e13a2 BCR-ABL Transcripts Are Associated with Earlier Cytogenetic and Molecular Response Rates in CML-CP Treated with Imatinib

Katia B Pagnano, MD, Eliana C Miranda, Fernanda S Seguro, MD, Gustavo HR Magalhaes, MD, Nelma D Clementino, MD, Arthur Moellmann-Coelho, MD, Maryanna N Da Silva, Renato Centrone, MD, Monika Conchon, MD, Jaisson Bortolini, MD, Teresa Cristina Bortolheiro, MD, Valquiria Povoa, Luciana Nardinelli, Carmino Antonio De Souza, MD PhD, Israel Bendit, MD PhD

Blood (2017) 130 (Supplement 1): 1596.

https://doi.org/10.1182/blood.V130.Suppl_1.1596.1596

Published: 2017

NARROW

Potency and Efficacy of Pharmacological PIP4K2 Inhibitors in Acute Lymphoblastic Leukemia

Real-World Data for FLT3-Mutated Acute Myeloid Leukemia Patients Treated in Resource-Constrained Settings

Treatment- Free Remission in Chronic Myeloid Leukemia -Experience of a Single Brazilian Private Institution Using Imatinib Copies

Treatment-Free Response in Chronic Myeloid Leukemia Using Brazilian Imatinib Copies As First Line - Results from Two Prospective Clinical Trials

Rhoa Mutation Is a Potential Biomarker Associated with Adverse Prognosis and High- Tumor Burden in Patients with Nodal Peripheral Lymphomas with T-Helper Follicular Phenotype (nPTCL-Thf): Data from a Brazilian Retrospective Cohort of Nodal PTCL

Chronic Myeloid Leukemia: Comparison of Survival between Pregnant and Non-Pregnant Women

Clinical, Laboratory, and Genetic Features of Erdheim-Chester Disease Patients from Two Reference Centers in a Developing Country

COVID-19 in Chronic Myeloid Leukemia Patients - Brazilian Experience

Co-occurrence of DNMT3A , NPM1 , FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis

Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial

Duration of Major Molecular Response and Discontinuation in Deep Molecular Response (MR4.5) Were Associated with Longer Treatment-Free Survival after Imatinib Discontinuation - Results from Two Prospective Brazilian Trials

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts

Molecular-Based Score Inspired on Metabolic Signature Improves Prognostic Stratification for Myelodysplastic Syndrome

Financial Impact of Imatinib Discontinuation in Brazil - a Pharmoeconomic Study

Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia

WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil

Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study

Impact of Treatment Free Remission (TFR) with Nilotinib in 2 nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment

E14a2 and e14a2+e13a2 BCR-ABL Transcripts Are Associated with Earlier Cytogenetic and Molecular Response Rates in CML-CP Treated with Imatinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only